Avalo Therapeutics, Inc. AVTX
15.47
(0.25)
(1.59%)
as of 25 Sep
- Market cap
- $843.1M
- P/E
- 0.0×
Follow AVTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
14.01 | 7.60 | 7.08 | 18.95 | |
Current Ratio |
14.28 | 8.14 | 7.66 | 19.31 | |
Net Debt/EBITDA |
5.84 | 4.97 | 3.93 | 12.71 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.53 | 1.04 | 0.90 | 0.55 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.08 | 0.09 | 0.11 | 0.02 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.17) | (1.06) | (0.88) | (0.46) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.17) | (1.06) | (0.88) | (0.46) | |
Cash per Share |
7.98 | 7.34 | 4.09 | 9.18 | |
Shareholders Equity per Share |
6.54 | 6.20 | 3.40 | 10.29 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.54 | 6.20 | 3.40 | 10.29 | |
Free Cash Flow |
(16.36) | (14.25) | (17.69) | (19.99) | |
Working Capital |
105.87 | 92.35 | 77.23 | 386.80 | |
Net Current Asset Value |
80.29 | 71.88 | 57.26 | 365.81 | |
EV/EBIT |
— | — | — | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
| Other line items | |||||
Average Payables |
1.14 | 0.21 | 0.52 | 2.86 | |
Average Assets |
111.78 | 133.60 | 119.20 | 308.68 | |
Average Common Equity |
56.31 | 108.04 | 95.47 | 276.62 |
Columns are period end dates